Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.32 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286114 | 1.00 | LMNA (0.36) | LMNAJAK2JAK3MEN1KMT2A | |
| SCHEMBL2146832 | 0.84 | LMNA (0.41) | LMNAMEN1KMT2AGRIA1CACNG8 | |
| SCHEMBL2146836 | 0.84 | LMNA (0.41) | LMNAMEN1KMT2AGRIA1CACNG8 | |
| SCHEMBL5070804 | 0.81 | POLB (0.40) | LMNAMEN1KMT2AGRIA1CACNG8 | |
| SCHEMBL5069179 | 0.81 | POLB (0.40) | LMNAMEN1KMT2AGRIA1CACNG8 | |
| SCHEMBL5069177 | 0.81 | POLB (0.40) | LMNAMEN1KMT2AGRIA1CACNG8 | |
| SCHEMBL2290898 | 0.79 | GRIA1 (0.39) | LMNAJAK2JAK3MEN1KMT2A | |
| SCHEMBL2144967 | 0.79 | GRIA1 (0.39) | LMNAJAK2JAK3MEN1KMT2A | |
| SCHEMBL2146834 | 0.78 | LMNA (0.37) | LMNAMEN1KMT2AGRIA1CACNG8 | |
| SCHEMBL2146839 | 0.78 | LMNA (0.37) | LMNAMEN1KMT2AGRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | claimed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | claimed |
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | disclosed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | LMNA 3473/4885JAK2 733/4885JAK3 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.